HLB Shares Plunge to Daily Limit After FDA Rejects Liver Cancer Drug
HLB shares plunged nearly 30% to their daily limit on the 10th after the U.S. FDA issued a third Complete Response Letter for its liver cancer drug rivoceranib, citing manufacturing facility issues.
Read the full articleYou might also wanna read
HLB liver cancer drug hits FDA setback again over manufacturing issues
HLB's hopes of bringing its liver cancer treatment to the US market have suffered another blow after the US Food and Drug Administration iss
AstraZeneca Plunges After New Heart Disease Drug Fails Trial
AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg. The post AstraZeneca
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
US FDA approves AbbVie's rare blood cancer drug
US FDA approves AbbVie's rare blood cancer drug reut.rs/4tTXtZ3
Una combinación de medicamentos dirigidos produce remisiones duraderas en las personas con linfoma de células B de crecimiento rápido resistente al tratamiento
Los tumores de más de la mitad de los participantes que recibieron tratamiento con venetoclax, ibrutinib, prednisona, obinutuzumab y lenalid
Comments
Sign in to join the conversation.
No comments yet. Be the first.